{
  "ticker": "ONC",
  "company_name": "BeOne Medicines Ltd.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06120283",
      "title": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer",
      "start_date": "2023-12-01",
      "completion_date": "2028-06",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT06029127",
      "title": "A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Non-Small Cell Lung Cancer",
      "start_date": "2023-10-23",
      "completion_date": "2024-12-31",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT06598800",
      "title": "Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced Solid Tumor",
      "start_date": "2024-10-18",
      "completion_date": "2028-09-30",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT05381909",
      "title": "A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult",
      "start_date": "2022-07-06",
      "completion_date": "2025-07-25",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT03736889",
      "title": "Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "MSI-H/dMMR Solid Tumors",
      "start_date": "2018-09-19",
      "completion_date": "2027-09",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT07005713",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Chronic Spontaneous Urticaria",
      "start_date": "2025-07-19",
      "completion_date": "2026-09-22",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT05981703",
      "title": "A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced Solid Tumor, Solid Tumor",
      "start_date": "2023-09-21",
      "completion_date": "2027-09-30",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT06233942",
      "title": "Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced Solid Tumor",
      "start_date": "2024-04-12",
      "completion_date": "2028-05-15",
      "enrollment": 0,
      "sponsor": "BeOne Medicines"
    },
    {
      "nct_id": "NCT05635708",
      "title": "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer",
      "start_date": "2023-03-07",
      "completion_date": "2026-10",
      "enrollment": 0,
      "sponsor": "BeiGene"
    },
    {
      "nct_id": "NCT04973605",
      "title": "A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Relapsed/Refractory Multiple Myeloma",
      "start_date": "2021-09-16",
      "completion_date": "2026-11",
      "enrollment": 0,
      "sponsor": "BeOne Medicines"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 23,
      "PHASE2": 10,
      "PHASE1, PHASE2": 7,
      "PHASE3": 9,
      "": 1
    },
    "by_status": {
      "RECRUITING": 34,
      "COMPLETED": 4,
      "TERMINATED": 1,
      "ACTIVE_NOT_RECRUITING": 8,
      "NOT_YET_RECRUITING": 2,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 43,
    "completed_trials": 4,
    "conditions": [
      "Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm",
      "Advanced Malignancies",
      "Advanced Solid Tumor",
      "Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer",
      "Advanced Solid Tumor, Metastatic Solid Tumor",
      "Advanced Solid Tumor, Solid Tumor",
      "Advanced Solid Tumors",
      "Advanced or Metastatic MTAP-deleted Solid Tumors",
      "B Cell Precursor Acute Lymphoblastic Leukemia",
      "B-cell Malignancies",
      "B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenstr\u00f6m Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma",
      "B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma",
      "Breast Cancer, Advanced Solid Tumor",
      "CLL",
      "Chronic Lymphocytic Leukemia",
      "Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma",
      "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
      "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)",
      "Chronic Spontaneous Urticaria",
      "Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage",
      "Extensive Stage Small Cell Lung Cancer",
      "Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma",
      "Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma",
      "Healthy Volunteers",
      "Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer",
      "MSI-H/dMMR Solid Tumors",
      "Mantle Cell Lymphoma",
      "Mantle Cell Lymphoma, B Cell Lymphoma",
      "Mature B-cell Malignancies",
      "Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer",
      "Non-Small Cell Lung Cancer",
      "Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer",
      "Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma",
      "Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia",
      "Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma",
      "Relapsed/Refractory Multiple Myeloma",
      "Resectable Esophageal Squamous Cell Carcinoma",
      "Rheumatoid Arthritis",
      "Solid Tumor",
      "Solid Tumor, Adult",
      "Solid Tumors, Advanced Solid Tumor",
      "Urothelial Carcinoma",
      "Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma",
      "Waldenstr\u00f6m's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:38.692366",
    "search_query": "BeOne Medicines Ltd.",
    "url": "https://clinicaltrials.gov/search?term=BeOne+Medicines+Ltd."
  }
}